Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | ICMT | O60725 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856026 | 0.91 | BRD4 (0.36) | GABRA1GABRA2TLR8BRD4 | |
| SCHEMBL2427045 | 0.83 | TLR8 (0.37) | GABRA1GABRA2TLR8ICMTBRD4 | |
| SCHEMBL2424583 | 0.83 | TLR8 (0.37) | GABRA1GABRA2TLR8ICMTBRD4 | |
| SCHEMBL14715147 | 0.83 | CNR2 (0.34) | GABRA1GABRA2TLR8ICMTCHRM4 | |
| SCHEMBL3848615 | 0.82 | TLR8 (0.39) | GABRA1GABRA2TLR8ICMTBRD4 | |
| SCHEMBL11886663 | 0.81 | GABRA1 (0.37) | GABRA1GABRA2TLR8ICMTBRD4 | |
| SCHEMBL2429557 | 0.79 | TLR8 (0.38) | TLR8ICMTBRD4TRPV3 | |
| SCHEMBL2426109 | 0.79 | TLR8 (0.38) | TLR8ICMTBRD4TRPV3 | |
| SCHEMBL11886664 | 0.78 | TLR8 (0.45) | GABRA1GABRA2TLR8ICMTBRD4 | |
| SCHEMBL2426406 | 0.78 | TLR8 (0.39) | TLR8ICMTBRD4TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | claimed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | claimed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | claimed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | claimed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009472-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | GABRA1 566/4885GABRA2 532/4885TLR8 1690/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | GABRA1 566/4885GABRA2 532/4885TLR8 1690/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | GABRA1 566/4885GABRA2 532/4885TLR8 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.